MyMD Pharmaceuticals (NASDAQ:MYMD) Shares Down 4.1%

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMDGet Free Report) shares traded down 4.1% during mid-day trading on Monday . The stock traded as low as $1.86 and last traded at $1.86. 39,968 shares traded hands during trading, a decline of 74% from the average session volume of 153,066 shares. The stock had previously closed at $1.94.

MyMD Pharmaceuticals Stock Performance

The company’s 50 day simple moving average is $2.33 and its 200-day simple moving average is $3.78.

MyMD Pharmaceuticals (NASDAQ:MYMDGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($5.14) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On MyMD Pharmaceuticals

An institutional investor recently raised its position in MyMD Pharmaceuticals stock. Mirae Asset Global Investments Co. Ltd. increased its position in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMDFree Report) by 230.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,108,473 shares of the company’s stock after acquiring an additional 2,167,871 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 6.11% of MyMD Pharmaceuticals worth $804,000 at the end of the most recent quarter. Institutional investors own 9.64% of the company’s stock.

MyMD Pharmaceuticals Company Profile

(Get Free Report)

MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.

Further Reading

Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with's FREE daily email newsletter.